Study of Cannabidiol and Neuroimaging on Stress

Dysregulation in stress responsivity is a growing psychiatry-transdiagnostic fundamental phenomenon, with limited therapeutic strategies. With the legalization of medical and recreational cannabis, many people consume cannabidiol (CBD; a nonintoxicating cannabinoid) to alleviate stress response, without the benefit of scientific guidance. To address this gap, the investigators propose a rigorous translational neuroscience study in a clinical high-risk population to define the roles of CBD in stress response with mechanisms of mesocorticolimbic-network function and hierarchy, neurometabolic, endocrine, and behavior, building upon convergent evidence from animal models and human evidence from our laboratories.

NCT Number	NCT07278505
Lead Sponsor	Icahn School of Medicine at Mount Sinai Collaborators: Jazz Pharmaceuticals, National Institute of Mental Health (NIMH)
Conditions	Early Life Adversity, Trauma, Stress
Enrollment	160 participants
Start Date	2025-10-28
Primary Completion	2030-02-28 (estimated)
Study Completion	2030-02-28 (estimated)
Updated on ClinicalTrials.gov	2025-12-12